Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) for the reporting period ending April 22, 2013, covering events occurring between April 17 and April 22, 2013. The company is a clinical-stage biopharmaceutical firm focused on developing cell-based therapies.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Events
- April 17, 2013: Received FDA approval to commence a Phase II clinical trial for NSI-566 in the treatment of amyotrophic lateral sclerosis (ALS).
- April 18, 2013: Announced that CEO Richard Garr will participate in a Bio Maryland panel at the BIO International Convention in Chicago on April 24, 2013.
- April 22, 2013: Received FDA approval to begin dosing the third and final cohort of patients in the ongoing Phase Ib clinical trial for NSI-189 in the treatment of major depressive disorder.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of regulatory milestones. The filing indicates significant progress in the company's clinical pipeline, specifically advancing NSI-566 to Phase II and concluding the dosing phase for NSI-189. No specific financial guidance, risk factors, or contingencies are detailed in this specific report.
Investor Verification Checklist
- Verify the company name is Neuralstem, Inc., as the input metadata incorrectly referenced Palisade Bio, Inc.
- Review the attached press releases (Exhibits 99.01, 99.02, 99.03) for detailed trial protocols and timelines.
- Check subsequent filings (10-Q or 10-K) for financial impact and cash runway, as this 8-K contains no financial data.
- Monitor the outcomes of the Phase II ALS trial and the final cohort of the Phase Ib depression trial.